SC
TCRX icon

Stempoint Capital’s TScan Therapeutics TCRX Stock Holding History

Stempoint Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-860,951
Closed -$4.29M – 75
2024
Q3 		$4.29M Buy
860,951
+15,882
+2% +$95.8K 1.28% 24
2024
Q2 		$4.94M Buy
+845,069
New +$6.66M 1.45% 23

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Stempoint Capital's TCRX Position: Q4 2024 in Review

Stempoint Capital sold out of TScan Therapeutics (TCRX) in Q4 2024, closing a stake of 860,951 shares — an estimated $4.29M sold.

Stempoint Capital first reported a position in TCRX in Q2 2024 and held it in 2 quarters. The position peaked at $4.94M in Q2 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q4 2024.

  • Stempoint Capital reported no remaining TScan Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Stempoint Capital sold 860,951 TScan Therapeutics shares in Q4 2024, an estimated $4.29M.
  • Stempoint Capital first reported a position in TScan Therapeutics in Q2 2024 and held it in 2 quarters.
  • Stempoint Capital's TScan Therapeutics position peaked at $4.94M in Q2 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.